Scientists at Sinai Health and the University of Toronto say a new drug designed to block an enzyme essential for the survival of specific cancer cells shows promise in curbing tumor growth. The preclinical findings, published in the journal Nature, describe a new drug designed with CRISPR-Cas9 gene-editing technology in the lab of Daniel Durocher, a senior investigator...